We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Makers of branded opioid pain relievers that want to claim their drugs are resistant to abuse must, in most cases, subject their products to three forms of tests to show the FDA how effectively they prevent misuse. Read More
Generics makers may soon have a new way to challenge first-filer marketing exclusivity held by their rivals under certain circumstances after a federal appeals court reinstated a lawsuit from Apotex. Read More
The European Medicines Agency is revising the way drugmakers conduct studies for drugs to treat blood clots, for the first time separating out the clinical requirements for different types of clots. Read More
Mylan is recalling two injectables — a hypertension drug and cancer treatment — due to quality control issues. Both drugs were manufactured in India. Read More
The U.S. government has awarded BioCryst $12.1 million for further development of its BCX4430 antiviral that targets multiple pathogens — including Ebola. Read More
Drugmakers in the European Union will pay slightly lower fees starting today, under an annual adjustment that reflects the inflation rate for the previous year. Read More
Teva is expanding its footprint in the central nervous system treatment market with the $3.2 billion purchase of movement disorders drugmaker Auspex Pharmaceuticals. Read More
The FDA has reopened the comment period on a guidance meant to make it easier for drugmakers to test products containing live biotherapeutics. Read More
Consumer group Public Citizen is calling on the FDA to send warning letters to four drugmakers to withdraw ads for five Type 2 diabetes drugs promoting off-label uses for weight loss or blood pressure reduction. Read More